Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Importance Systemic treatments for atopic dermatitis are being evaluated primarily in
placebo-controlled trials; network meta-analysis can provide relative efficacy and safety …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Background Systemic therapies are typically combined with topical corticosteroids for the
management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase …

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating
inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors …

In the past few decades, biological drugs and small molecule inhibitors targeting
inflammatory cytokines, immune cells, and intracellular kinases have become the standard …

abstract Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin
lesions. The knowledge on the pathogenesis of AD is driving the development of new drugs …

Janus kinase (JAK) inhibitors have become promising treatments for atopic dermatitis (AD),
however no study directly comparing JAK inhibitors with each other has been reported. We …